Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Replimune Group, Inc. Director's Dealing 2022

Dec 6, 2022

33193_dirs_2022-12-05_7e53b8fe-de4e-4dcf-8c5d-68006a53911c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Replimune Group, Inc. (REPL)
CIK: 0001737953
Period of Report: 2022-12-01

Reporting Person: Xynos Konstantinos (Chief Medical Officer)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 37500 Direct
Common Stock 7000 Direct
Common Stock 8798 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Employee Stock Option (right to buy) $28.62 2031-11-29 Common Stock (75000) Direct
Employee Stock Option (right to buy) $18.26 2032-04-01 Common Stock (10500) Direct

Footnotes

F1: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The Reporting Person was granted 50,000 RSUs on November 29, 2021, 25% of such RSUs vested and were released on November 15, 2022, and the remainder will vest in three approximately equal annual installments thereafter until November 15, 2025, subject to the Reporting Person's continuous service to the Issuer.

F2: Represents shares of the Issuer's common stock issuable upon settlement of RSUs granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The Reporting Person was granted 7,000 RSUs on April 1, 2022, 25% of such RSUs vest on May 15, 2023, and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2026, subject to the Reporting Person's continuous service to the Issuer.

F3: 25% of the shares underlying this stock option vested on November 29, 2022, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.

F4: 25% of the shares underlying this stock option vest on April 1, 2023, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.